In IMMUNCIRC, we want to investigate the role of the T cells and microbiota composition in immunotherapy response. Moreover, we want to predict and monitor immunotherapy response to maximize the benefit of treatment, prompting the field towards precision immuno-oncology.

Circulating tumor DNA (ctDNA) will be measured by looking at genomic and epigenetic variants using cfMeDIP-seq. T cell clone composition and ctDNA levels will be measured longitudinally during treatment in metastatic RCC patients and the role of the colonic microflora in immunotherapy response will be determined from rectal swabs.
Effektiv start/slut dato01/08/202301/07/2029